Jiangsu Kanion Stock Hits Day Low of CNY 12.82 Amid Price Pressure

Jiangsu Kanion Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 5.72% on July 17, 2026. The stock reached an intraday low of CNY 12.82, reflecting ongoing challenges within the company. Over the past year, Jiangsu Kanion has faced significant headwinds, with a year-to-date performance of -8.93% and a troubling annual decline of 21.84%. In comparison, the China Shanghai Composite index has shown a more favorable performance, gaining 7.03% over the same period. The company's financial metrics indicate a concerning trend, with net sales decreasing at an annual rate of 1.96% and operating profit declining by 16.74% over the last five years. Additionally, the company has reported negative results for the last two consecutive quarters, contributing to its underperformance against the benchmark. Despite a market capitalization of CNY 6,929 million and a P/E ratio of 23.00, Jiangsu Kanion's return on equity stands at 6.16%, highlighting the challenges it faces in maintaining growth and profitability in the competitive pharmaceuticals and biotechnology sector.